SNTA has suffered mightily due to the legitimate re-balancing of portfolio's out of the high flying bio-tech's to other value sector plays. The sell off of SNTA however is an example of the baby thrown out with the bathwater. For a bio-tech the potential of SNTA makes the current price a value play. It is a matter of time before the market sees this. The rebound for SNTA should happen way before we can confirm if the pipeline will be successful. If the pipeline is successful we will be in the teens next year but even before that the potential is worth way more that $4 due to the excellent probability of success (IHMO).